Atea Pharmaceuticals, Inc. (AVIR) News
Track canonical SquawkNews coverage tagged to AVIR, Atea Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
AVIR Reports Q2 2026 Financial Results
Atea Pharmaceuticals reports second quarter 2026 financial results and provides business update
EARNINGS | Aug 12, 2026, 08:06 PM UTC
L
AVIR - Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 - Click For
AVIR - Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
EARNINGS | Aug 05, 2026, 11:00 AM UTC
L
AVIR - Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbu
AVIR - Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
EQUITY | Jul 28, 2026, 11:00 AM UTC
L
AVIR Atea Pharmaceuticals initiates first-in-human phase 1 clinical trial of at-587 for the treatment of hepatitis e virus
AVIR Atea Pharmaceuticals initiates first-in-human phase 1 clinical trial of at-587 for the treatment of hepatitis e virus
EQUITY | Jul 14, 2026, 11:02 AM UTC
M
AVIR Completes Enrollment
Atea Pharmaceuticals completes patient enrollment in Phase 3 C-FORWARD trial for Hepatitis C treatment
EQUITY | Jun 25, 2026, 11:00 AM UTC